WO2023090495A1 - 열 안정성이 우수한 알룰로스 에피머화 효소 변이체, 이의 제조방법 및 이를 이용한 알룰로스의 제조방법 - Google Patents
열 안정성이 우수한 알룰로스 에피머화 효소 변이체, 이의 제조방법 및 이를 이용한 알룰로스의 제조방법 Download PDFInfo
- Publication number
- WO2023090495A1 WO2023090495A1 PCT/KR2021/017155 KR2021017155W WO2023090495A1 WO 2023090495 A1 WO2023090495 A1 WO 2023090495A1 KR 2021017155 W KR2021017155 W KR 2021017155W WO 2023090495 A1 WO2023090495 A1 WO 2023090495A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- allulose
- epimerase
- amino acid
- variant
- epimerase variant
- Prior art date
Links
- LKDRXBCSQODPBY-JDJSBBGDSA-N D-allulose Chemical compound OCC1(O)OC[C@@H](O)[C@@H](O)[C@H]1O LKDRXBCSQODPBY-JDJSBBGDSA-N 0.000 title claims abstract description 171
- 238000002360 preparation method Methods 0.000 title description 3
- 229930091371 Fructose Natural products 0.000 claims abstract description 66
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 66
- 239000005715 Fructose Substances 0.000 claims abstract description 66
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 60
- 238000004519 manufacturing process Methods 0.000 claims abstract description 24
- 108091033319 polynucleotide Proteins 0.000 claims description 54
- 102000040430 polynucleotide Human genes 0.000 claims description 54
- 239000002157 polynucleotide Substances 0.000 claims description 53
- 239000000203 mixture Substances 0.000 claims description 20
- 239000002773 nucleotide Substances 0.000 claims description 18
- 125000003729 nucleotide group Chemical group 0.000 claims description 18
- 239000013598 vector Substances 0.000 claims description 17
- 239000006166 lysate Substances 0.000 claims description 11
- 238000012258 culturing Methods 0.000 claims description 4
- 101001008613 Arthrobacter globiformis Ketose 3-epimerase Proteins 0.000 abstract description 39
- 102000004190 Enzymes Human genes 0.000 abstract description 34
- 108090000790 Enzymes Proteins 0.000 abstract description 34
- 241001134569 Flavonifractor plautii Species 0.000 abstract description 24
- 230000000694 effects Effects 0.000 abstract description 15
- 125000000539 amino acid group Chemical group 0.000 abstract description 10
- 238000011109 contamination Methods 0.000 abstract description 2
- 108090001066 Racemases and epimerases Proteins 0.000 description 74
- 229960002737 fructose Drugs 0.000 description 63
- 238000006243 chemical reaction Methods 0.000 description 35
- 238000000034 method Methods 0.000 description 27
- 102220072552 rs746207 Human genes 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 19
- 239000013604 expression vector Substances 0.000 description 16
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 15
- 239000012634 fragment Substances 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 11
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 9
- 229910021645 metal ion Inorganic materials 0.000 description 9
- 108091008146 restriction endonucleases Proteins 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000004471 Glycine Substances 0.000 description 7
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 7
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 229960000310 isoleucine Drugs 0.000 description 5
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 5
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 5
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 5
- 229930182817 methionine Natural products 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 235000010413 sodium alginate Nutrition 0.000 description 5
- 239000000661 sodium alginate Substances 0.000 description 5
- 229940005550 sodium alginate Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000013599 cloning vector Substances 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229910001437 manganese ion Inorganic materials 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 238000007857 nested PCR Methods 0.000 description 3
- 229910001453 nickel ion Inorganic materials 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 101710201279 Biotin carboxyl carrier protein Proteins 0.000 description 2
- 241000186226 Corynebacterium glutamicum Species 0.000 description 2
- 108030002100 D-tagatose 3-epimerases Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000662772 Flavonifractor Species 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 241000589180 Rhizobium Species 0.000 description 2
- 241000235088 Saccharomyces sp. Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000012533 medium component Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 238000000455 protein structure prediction Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000005030 transcription termination Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- FMYBFLOWKQRBST-UHFFFAOYSA-N 2-[bis(carboxymethyl)amino]acetic acid;nickel Chemical compound [Ni].OC(=O)CN(CC(O)=O)CC(O)=O FMYBFLOWKQRBST-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 244000298479 Cichorium intybus Species 0.000 description 1
- 235000007542 Cichorium intybus Nutrition 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 241000186249 Corynebacterium sp. Species 0.000 description 1
- 150000008165 D-ketoses Chemical class 0.000 description 1
- BJHIKXHVCXFQLS-PUFIMZNGSA-N D-psicose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C(=O)CO BJHIKXHVCXFQLS-PUFIMZNGSA-N 0.000 description 1
- LKDRXBCSQODPBY-OEXCPVAWSA-N D-tagatose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@@H]1O LKDRXBCSQODPBY-OEXCPVAWSA-N 0.000 description 1
- 101710109941 D-tagatose 3-epimerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108091006054 His-tagged proteins Proteins 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- 101710141886 Ketose 3-epimerase Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241001135312 Sinorhizobium Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 241000015793 Treponema primitia Species 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 241000193453 [Clostridium] cellulolyticum Species 0.000 description 1
- 210000000579 abdominal fat Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229940097012 bacillus thuringiensis Drugs 0.000 description 1
- BVGLIYRKPOITBQ-ANPZCEIESA-N benzylpenicillin benzathine Chemical compound C=1C=CC=CC=1C[NH2+]CC[NH2+]CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 BVGLIYRKPOITBQ-ANPZCEIESA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000012824 chemical production Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910001429 cobalt ion Inorganic materials 0.000 description 1
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- -1 molybdate ions Chemical class 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N monoethanolamine hydrochloride Natural products NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- 230000018791 negative regulation of catalytic activity Effects 0.000 description 1
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- XRARAKHBJHWUHW-UHFFFAOYSA-N subcusine Natural products OC1C2C3C4(C5C6OC)C(O)CCC5(COC)CN(CC)C4C6C2(O)CC(OC)C1C3 XRARAKHBJHWUHW-UHFFFAOYSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/02—Monosaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y501/00—Racemaces and epimerases (5.1)
- C12Y501/03—Racemaces and epimerases (5.1) acting on carbohydrates and derivatives (5.1.3)
Definitions
- the present invention relates to allulose epimerase variants and the like, and more particularly, to Flavonifractor plautii Conversion rate and thermal stability of fructose to allulose compared to D-allulose 3-epimerase derived from This improved allulose epimerase variant and various inventions derived therefrom are directed.
- D-allulose is also called D-psicose as an epimer of carbon 3 of fructose.
- D-allulose has 70% sweetness compared to sugar (Oshima 2006), but only 0.3% energy, so it is a functional monosaccharide that can be applied as a low-calorie sweetener for diet foods (Matsuo et al. 2002).
- D-allulose has the function of suppressing glucose absorption and blood sugar, so it can be applied to food and beverages for diabetic patients and food and beverages for reception, and through inhibition of enzyme activity involved in lipid synthesis in the liver. Since it can suppress abdominal fat accumulation, it can be used in various functional foods such as health foods (Matsuo et al. 2001; Iida et al. 2008; Hayashi et al. 2010; Hossain et al. 2011).
- D-tagatose 3-epimerase derived from Rhizobium speroides was inserted into E. coli to transform it, and then D-tagatose 3-epimerase expressed in the transformed E. coli was transformed. Allulose was produced from fructose.
- Korean Patent Registration No. 10-0744479 discloses a method for producing allulose by an allulose epimerase derived from Agrobacterium tumefaciens.
- Korean Patent Registration No. 10-0832339 discloses Sinorhizobium YB-58 KCTC 10983BP having an activity of converting fructose into allulose and a method of converting fructose into allulose using the same.
- Korean Patent Registration No. 10-1106253 discloses E.
- Korean Patent Registration No. 10-1339443 discloses ketose 3-epimerase derived from a microorganism belonging to the genus Rhizobium .
- a method for converting fructose into allulose using the same is disclosed, and Korean Patent Registration No.
- 10-1318422 discloses D-allulose 3-epimerase derived from Clostridiuim scindens and A method for producing allulose from fructose using this is disclosed, and Korean Patent Registration No. 10-1473918 discloses a D-allulose 3-epimerase derived from Flavonifractor plautii and the same A method for producing allulose from fructose using
- wild-type D-allulose 3-epimerase derived from microorganisms does not have a high conversion rate of fructose to allulose and has low thermal stability, so it is rapidly deactivated at the optimum activation temperature, making it unsuitable for industrialization. not. Therefore, it is necessary to develop a novel D-allulose 3-epimerase mutant with improved conversion rate of fructose to allulose or thermal stability compared to wild type D-allulose 3-epimerase derived from microorganisms. do.
- 10-2014-0021974 related to D-allulose 3-epimerase variants discloses Treponema monia showing fast allulose conversion rate and stability at high temperature by inducing mutations at the gene level.
- ZAS-1-derived D-allulose 3-epimerase is disclosed, and
- Korean Patent Registration No. 10-1203856 discloses a mutation of wild-type allulose epimerase derived from Agrobacterium tumefaciens. Allulose epimerase variants with improved thermal stability obtained through In addition, Korean Patent Registration No.
- 10-2254411 discloses glycine, an amino acid residue present at position 216 in the amino acid sequence of wild-type D-allulose 3-epimerase derived from Flavonifractor plautii ( A novel allulose epimerase variant in which Gly) is substituted with serine (Ser) is disclosed, and Korean Patent Publication No. 10-2021-0132405 discloses wild-type D-derived from Flavonifractor plautii .
- the present invention was derived under the background of the prior art, and the first object of the present invention is the conversion rate and heat of fructose to allulose compared to wild-type D-allulose 3-epimerase derived from Flavonifractor plautii. It is to provide a novel D-allulose 3-epimerase variant with improved stability.
- a second object of the present invention is to provide a method for preparing a novel D-allulose 3-epimerase variant or various elements necessary for preparing a novel D-allulose 3-epimerase variant.
- a third object of the present invention is to provide a method for producing allulose from fructose or various elements necessary for producing allulose from fructose.
- glycine an amino acid residue present at position 216 in the amino acid sequence of wild-type D-allulose 3-epimerase derived from Flavonifractor plautii, is serine (Ser) [Republic of Korea Registered Patent Publication No. 10-2254411 (2021.05.14)] for a novel allulose epimerase variant substituted with, and wild-type derived from Flavonifractor plautii
- Ser serine
- a patent application has been filed for a novel allulose epimerase variant in which methionine (Met) at position 234 is substituted with isoleucine (Ile) [Korean Patent Publication No. 10-2021-0132405 (2021.11.04)].
- the allulose epimerase variants disclosed in Korean Patent Registration No. 10-2254411 and Korean Patent Publication No. 10-2021-0132405 are wild-type D-allulose 3-epi derived from Flavonifractor plautii Thermal stability is improved compared to merase, but when the conversion reaction of fructose to allulose is carried out for a long time at a high temperature of 60 ° C.
- the inventors of the present invention utilize protein structure prediction technology to improve the conversion rate and thermal stability of fructose to allulose of the allulose epimerase variant disclosed in Korean Patent Publication No. 10-2021-0132405 to improve the conversion rate and thermal stability Additional amino acid residue position candidates expected to be related to improvement are derived, and only when the amino acid residue at a specific position among them is substituted with another amino acid residue Conversion rate of fructose to allulose and thermal stability are improved. completed the present invention.
- the present invention provides an allulose epimerase variant consisting of the amino acid sequence of SEQ ID NO: 5.
- the present invention provides a polynucleotide encoding an allulose epimerase variant consisting of the amino acid sequence of SEQ ID NO: 5.
- the present invention provides a recombinant vector comprising a polynucleotide encoding an allulose epimerase variant consisting of the amino acid sequence of SEQ ID NO: 5.
- the present invention provides a polynucleotide encoding an allulose epimerase variant consisting of the amino acid sequence of SEQ ID NO: 5 or a recombinant strain transformed with a recombinant vector containing the polynucleotide.
- the present invention cultivates a polynucleotide encoding an allulose epimerase variant consisting of the amino acid sequence of SEQ ID NO: 5 or a recombinant strain transformed with a recombinant vector containing the polynucleotide to obtain an allulose epimerase variant expressing; and isolating the allulose epimerase variant from the lysate of the recombinant strain in which the allulose epimerase variant is expressed.
- the present invention provides a composition for producing allulose comprising an allulose epimerase variant consisting of the amino acid sequence of SEQ ID NO: 5.
- the present invention is a polynucleotide encoding an allulose epimerase variant consisting of the amino acid sequence of SEQ ID NO: 5 or a recombinant strain transformed by a recombinant vector containing the polynucleotide, a culture of the recombinant strain, or the recombinant
- Provided is a composition for producing allulose comprising a lysate of the strain.
- the present invention provides a method for preparing allulose comprising reacting fructose with an allulose epimerase variant having the amino acid sequence of SEQ ID NO: 5 or a composition comprising the allulose epimerase variant.
- the present invention is a polynucleotide encoding an allulose epimerase variant consisting of the amino acid sequence of SEQ ID NO: 5 or a recombinant strain transformed with a recombinant vector containing the polynucleotide, a culture of the recombinant strain, It provides a method for producing allulose comprising the step of reacting with a lysate of the recombinant strain or a composition containing any one or more of them.
- the novel allulose epimerase variant according to the present invention is a wild-type D-allulose 3-epimerase or D-allulose epimerase variant W29K/G216S/M234I derived from Flavonifractor plautii. Conversion activity of fructose into allulose is higher than that of fructose, and thermal stability is excellent, especially under high temperature conditions of 60°C or higher, so contamination can be prevented and production time can be reduced during the industrial-level enzymatic conversion reaction for mass production of allulose. and can reduce production costs.
- Figure 1 shows a total of four amino acid residue positions selected as substitution candidates to improve the conversion rate of fructose to allulose and thermal stability of the D-allulose epimerase variant W29K/G216S/M234I by the inventors of the present invention.
- Allulose epimerase variant W29K / A77S / G216S / M234I is the amino acid sequence (SEQ ID NO: In 1), tryptophan (Trp) at position 29 is substituted with lysine (Lys), alanine (Als) at position 77 is substituted with serine (Ser), and glycine (Gly) at position 216 is substituted with It is substituted with serine (Ser) and at the same time methionine (Met) present at the 234th position is substituted with isoleucine (Ile).
- the allulose epimerase variant W29K/A77S/G216S/M234I is a wild-type D-allulose 3-epimerase derived from Flavonifractor plautii or a variant W29K/G216S/M234I thereof. It has a higher conversion activity of fructose into allulose than , and has excellent thermal stability, especially under high temperature conditions of 60°C or higher.
- the D-allulose 3-epimerase variant W29K/G216S/M234I is 29 of the amino acid sequence (SEQ ID NO: 1) of wild-type D-allulose 3-epimerase derived from Flavonifractor plautii.
- Tryptophan (Trp) at position 216 is substituted with lysine (Lys), glycine (Gly) at position 216 is replaced with serine (Ser), and methionine (Met) at position 234 is replaced with isoleucine (Ile). ), and consists of the amino acid sequence of SEQ ID NO: 3, and the preparation method and characteristics are disclosed in Korean Patent Publication No. 10-2021-0132405.
- the allulose epimerase variant W29K / A77S / G216S / M234I is a poly encoding W29K / G216S / M234I
- a variant of wild-type D-allulose 3-epimerase derived from Flavonifractor plautii PCR is performed using a nucleotide (consisting of the nucleotide sequence of SEQ ID NO: 4) as a template and an oligonucleotide having a predetermined nucleotide sequence as a primer pair, and then using the pair of amplified mutant fragments as a template and the sequence of the restriction enzyme recognition site After performing overlap extension PCR using the introduced oligonucleotide as a primer, and inserting a polynucleotide fragment encoding the amino acid sequence of the allulose epimerase variant into an expression vector to prepare a recombinant expression vector, the recombinant expression vector After transforming the host strain to prepare a
- polynucleotide encoding W29K/G216S/M234I which is a variant of the D-allulose 3-epimerase (consisting of the nucleotide sequence of SEQ ID NO: 4), is a wild type derived from Flavonifractor plautii .
- PCR is performed using a polynucleotide encoding D-allulose 3-epimerase (consisting of the nucleotide sequence of SEQ ID NO: 2) as a template and an oligonucleotide having a predetermined nucleotide sequence as a primer pair, and then amplified mutant It can be produced by performing overlap extension PCR using a pair of fragments as templates and oligonucleotides into which sequences of restriction enzyme recognition sites have been introduced as primers.
- the allulose epimerase variant W29K / A77S / G216S / M234I according to the present invention consists of the amino acid sequence of SEQ ID NO: 5, but the equivalent range of allulose epimerase variant W29K / A77S / G216S / M234I according to the present invention must be It is not limited to this.
- the equivalent range of the allulose epimerase variant W29K / A77S / G216S / M234I according to the present invention is SEQ ID NO: 5, as long as the activity of converting fructose to allulose and thermal stability at high temperatures of 60 ° C. or higher are maintained.
- Some amino acids in the amino acid sequence may be substituted, inserted and/or deleted.
- substitution of the amino acid is preferably performed by a conservative amino acid replacement that does not change the properties of the protein.
- modification of the amino acid may be achieved by glycosylation, acetylation, phosphorylation, and the like.
- the equivalent range of the allulose epimerase variant W29K / A77S / G216S / M234I according to the present invention increases the structural stability against heat, pH, etc. by mutation or modification on the amino acid sequence, or for the conversion of fructose to allulose. It may contain proteins with increased activity.
- the equivalent range of the allulose epimerase variant W29K / A77S / G216S / M234I according to the present invention is 70% or more, 80% or more, 90% or more, 95% or more of the amino acid sequence of any one of the amino acid sequences of SEQ ID NO: 5 It may contain an amino acid sequence having a homology of at least 99% or more.
- Another aspect of the present invention relates to a method for preparing the novel allulose epimerase variant W29K/A77S/G216S/M234I or various elements required to prepare the novel allulose epimerase variant W29K/A77S/G216S/M234I .
- Various elements required to prepare the novel allulose epimerase variant W29K/A77S/G216S/M234I include a polynucleotide, a primer pair, a recombinant vector, and a recombinant strain.
- the polynucleotide is a polynucleotide encoding an allulose epimerase variant consisting of the amino acid sequence of SEQ ID NO: 5, preferably consisting of the nucleotide sequence of SEQ ID NO: 9.
- polynucleotide refers to any polyribonucleotide (RNA) or polydeoxyribonucleotide (DNA) that is non-modified or modified.
- the polynucleotide includes single- or double-stranded DNA, DNA as a mixture of single- and double-stranded regions, single- and double-stranded RNA, RNA as a mixture of single- and double-stranded regions, or hybrid molecules thereof.
- the equivalent range of the polynucleotide encoding the allulose epimerase variant includes a sequence having substantial identity to the nucleotide sequence of SEQ ID NO: 9.
- the substantial identity is determined by aligning the nucleotide sequence of SEQ ID NO: 9 and any other sequence so as to correspond as much as possible, and analyzing the sequence so that the nucleotide sequence of SEQ ID NO: 9 is 70% or more, 90% or more, or having 98% or more sequence homology.
- a person skilled in the art can substitute, add, or delete one or more bases in the nucleotide sequence of the polynucleotide using a genetic recombination technique known in the art to obtain the same identity within the range having substantial homology. It will be readily appreciated that polynucleotides encoding active allulose epimerase variants can be prepared. Comparison of such homology can be performed by calculating homology between two or more sequences as a percentage (%) using a commercially available computer program.
- the primer pair is for synthesizing a polynucleotide encoding an allulose epimerase variant consisting of the amino acid sequence of SEQ ID NO: 5, encoding W29K / G216S / M234I, a variant of D-allulose 3-epimerase
- a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 4
- template it is composed of a forward primer and a reverse primer having the following nucleotide sequence.
- the recombinant vector includes a polynucleotide encoding an allulose epimerase variant consisting of the amino acid sequence of SEQ ID NO: 5.
- the recombinant vector may be provided in the form of inserting a polynucleotide encoding an allulose epimerase variant into a cloning vector or an expression vector using a known standard method.
- the term "cloning vector" used in the present invention is defined as a material capable of transporting a DNA fragment into a host cell and reproducing it.
- the cloning vector may further include a polyadenylation signal, a transcription termination sequence, and multiple cloning sites.
- the multiple cloning site includes at least one endonuclease restriction enzyme restriction site.
- the cloning vector may further include a promoter.
- the polynucleotide encoding the allulose epimerase variant W29K/A77S/G216S/M234I may be located upstream of the polyadenylation signal and transcription termination sequence.
- the term "expression vector” used in the present invention is defined as a DNA sequence necessary for transcription and translation of the cloned DNA in an appropriate host.
- expression vector refers to a genetic construct comprising essential regulatory elements operably linked to an insert such that the insert is expressed when present in cells of an individual.
- the expression vectors can be prepared and purified using standard recombinant DNA techniques.
- the type of the expression vector is not particularly limited as long as it expresses a desired gene in various host cells such as prokaryotic and eukaryotic cells and produces a desired protein, but retains a promoter showing strong activity and strong expression power in a natural state.
- a vector capable of producing a large amount of a foreign protein having a similar form is preferred.
- the expression vector preferably contains at least a promoter, a start codon, a gene encoding a desired protein, and a stop codon terminator.
- promoter means a minimal sequence sufficient to direct transcription.
- the promoter may include a promoter configuration sufficient to allow expression of a regulatable promoter-dependent gene induced by a cell type specific or external signal or agent, such a configuration located at the 5' or 3' portion of the gene. can do.
- promoters include both conserved promoters and inducible promoters.
- Promoter sequences may be of prokaryotic, eukaryotic or viral origin.
- operably linked means the association of polynucleotide sequences on a single polynucleotide so that the function of one is regulated by the other.
- a promoter when a promoter is capable of controlling expression of a coding sequence (i.e., when the coding sequence is under the transcriptional control of the promoter), the promoter operates in conjunction with the coding sequence, or the ribosome binding site is capable of facilitating translation. If located, the ribosome binding site is operatively linked to a coding sequence. Coding sequences can be operatively linked to regulatory sequences in either the sense or antisense orientation.
- a recombinant vector according to the present invention is preferably an expression vector.
- the recombinant strain is transformed with a polynucleotide encoding an allulose epimerase variant consisting of the amino acid sequence of SEQ ID NO: 5 or with a recombinant vector containing the polynucleotide.
- the term "recombinant strain” refers to a cell transformed by introducing a polynucleotide encoding one or more target proteins or an expression vector having the same into a host cell.
- Methods for preparing transformants by introducing the expression vector into host cells include transient transfection, microinjection, transduction, cell fusion, calcium phosphate precipitation, liposome-mediated transfection ( liposemmediated transfection), DEAE Dextran-mediated transfection, polybrene-mediated transfection, electroporation, electroinjection, PEG, etc.
- Host cells that can be transformed with the expression vector in the present invention are not particularly limited as long as they are known in the art, such as prokaryotic cells, plant cells, insect cells, and animal cells, and preferably have high DNA transduction efficiency.
- the host cell may be E. coli.
- E. coli examples include BL21, JM109, K-12, LE392, RR1, DH5 ⁇ or W3110, but are not limited thereto.
- Bacillus strains such as Bacillus subtilis and Bacillus thuringiensis, Corynebacterium strains such as Corynebacterium glutamicum, Salmonella strains such as Salmonella typhimurium, and other Serratia
- Bacillus strains such as Bacillus subtilis and Bacillus thuringiensis
- Corynebacterium strains such as Corynebacterium glutamicum
- Salmonella strains such as Salmonella typhimurium
- other Serratia It is also possible to use strains selected from the group consisting of enterobacteriaceae and strains such as Marcessons and various Pseudomonas species.
- the method for producing the allulose epimerase variant W29K / A77S / G216S / M234I is transformed by a polynucleotide encoding the allulose epimerase variant consisting of the amino acid sequence of SEQ ID NO: 5 or comprising the polynucleotide culturing the recombinant strain transformed with the recombinant vector to express an allulose epimerase variant; and isolating the psicose epimerase from the lysate of the recombinant strain expressing the allulose epimerase variant.
- Protein expression by host cells can be induced by using lactose, an inducing factor, IPTG (isopropyl-1-thio- ⁇ -D-galactopyranoside), etc., and the induction time is such that the amount of protein is maximized.
- lactose lactose
- IPTG isopropyl-1-thio- ⁇ -D-galactopyranoside
- an allulose epimerase variant can be recovered from a lysate of a recombinant strain.
- Cells used for protein expression can be disrupted by various physical or chemical means such as repeated freeze-thaw, sonication, mechanical disruption, or cell disintegrants, and can be isolated or purified by conventional biochemical separation techniques ( Sambrook et al., Molecular Cloning: A laborarory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, 1989; Deuscher, M., Guide to Protein Purification Methods Enzymology, Vol. 182. Academic Press. Inc., San Diego, CA , 1990).
- methods for separating or purifying proteins expressed by host cells include electrophoresis, centrifugation, gel filtration, precipitation, dialysis, chromatography (ion exchange chromatography, affinity chromatography, immunosorbent affinity chromatography, reverse phase HPLC, gel permeation HPLC), isoelectric focusing and various variations or combinations thereof methods.
- the step of separating the allulose epimerase variant from the lysate of the recombinant strain may be preferably performed by affinity chromatography using a peptide tag.
- the peptide tag is known as HA tag, FLAG tag, His tag, BCCP (biotin carboxyl carrier protein), c-myc tag, V5 tag, glutathione-S-transferase (GST) or MBP (maltose binding protein).
- a variety of tags can be used, preferably a double His tag. His-tagged proteins are specifically trapped on a column of Ni-NTA (nickel-nitrilotriacetic acid) resin and can be eluted with EDTA or imidazole.
- Another aspect of the present invention relates to a method for producing allulose from fructose or various elements required for producing allulose from fructose.
- Various elements required for producing allulose from the fructose include a composition for producing allulose.
- composition for producing allulose includes allulose epimerase variant W29K/A77S/G216S/M234I having the amino acid sequence of SEQ ID NO: 5.
- another example of the composition for producing allulose is a recombinant strain transformed with a polynucleotide encoding an allulose epimerase variant consisting of the amino acid sequence of SEQ ID NO: 5 or a recombinant vector containing the polynucleotide , A culture of the recombinant strain or a lysate of the recombinant strain.
- the composition for producing allulose may preferably further include at least one selected from the group consisting of manganese ions, nickel ions, and cobalt ions, and more preferably may further include manganese ions or nickel ions.
- the novel allulose epimerase variant according to the present invention exhibits metalloenzyme properties whose activation is controlled by metal ions, and the reaction by the enzyme is carried out in the presence of specific metal ions such as manganese ions or nickel ions. The production yield of allulose can be increased.
- one example of a method for preparing allulose from the fructose is to transform fructose with a polynucleotide encoding an allulose epimerase variant consisting of the amino acid sequence of SEQ ID NO: 5 or to a recombinant vector containing the polynucleotide and reacting with a composition comprising a recombinant strain transformed by, a culture of the recombinant strain, a lysate of the recombinant strain, or any one or more of them.
- the method for preparing allulose from fructose may further include adding metal ions, and the types of metal ions are as described above.
- the metal ion may be added to fructose as a substrate or to a mixture of an enzyme variant and fructose.
- the metal ion is added to the carrier on which the enzyme variant is immobilized (before adding fructose), added to a mixture of the carrier and fructose on which the enzyme variant is immobilized (after addition of fructose), or fructose and fructose when fructose is added. It can be added in the form of a mixture.
- the metal ion may be added to the culture or culture may be performed in a culture medium to which the metal ion is added.
- the allulose epimerase variant or the recombinant strain is preferably immobilized on a carrier.
- the carrier can create an environment in which the activity of the immobilized enzyme can be maintained for a long period of time, and can be selected from all known carriers that can be used for enzyme immobilization.
- sodium alginate may be used as the carrier.
- Sodium alginate is a natural colloidal polysaccharide that is abundantly present in the cell walls of seaweed. Formed by beta-1,4 bonds, it can stably immobilize strains or enzymes and can be advantageous in terms of allulose yield.
- a sodium alginate solution eg, sodium alginate aqueous solution
- w/v sodium alginate at a concentration of 1.5 to 4.0%
- the solution can be used for immobilization of recombinant strains.
- the reaction temperature is 60 to 70 ° C, preferably 60 to 67 ° C, more preferably 60 to 65 ° C, considering the stability and maximum activity of the enzyme variant,
- the reaction pH is in the range of 6.5 to 8, preferably 6.5 to 7.5, more preferably 6.5 to 7.
- the concentration of fructose is not particularly limited, but it is preferably 1 to 75% (w / w) based on the total reactants in consideration of productivity and economy, and 4 to 35% (w/w) is more preferred.
- the concentration of the enzyme variant used in the method for producing allulose from fructose is 0.001 to 0.5 mg/ml, preferably 0.01 to 0.2 mg/ml, more preferably 0.02 to 0.1 mg/ml based on the total reactants.
- the host strain of the recombinant strain is preferably a food-safe strain.
- the food-safe strain refers to a GRAS (generally accepted as safe) class strain generally recognized as safe, for example, Saccharomyces sp. strains ( Saccharomyces sp.), Bacillus sp. strains ( Bacillus sp .), It may be selected from Corynebacterium sp. and the like.
- the strains are industrial microorganisms that produce chemicals having various uses in fields such as feed, medicine, and food. These strains are strains that are easy to genetic manipulation and mass culture, or have high stability under various process conditions.
- these strains have a relatively rigid cell membrane structure compared to other bacteria, they exhibit biological characteristics in which the cells exist in a stable state even under the influence of osmotic pressure due to high sugar concentration.
- Specific examples of the GRAS (generally accepted as safe) class strain include Saccharomyces cerevisiae , Bacillus subtilis , and Corynebacterium glutamicum .
- Example 1 Additional exploration of amino acid substitution sites for improving the conversion rate and thermal stability of D-allulose 3-epimerase
- Applicant of the present invention is wild-type D-allulose 3-epi to improve the conversion rate of fructose to allulose and thermal stability of wild-type D-allulose 3-epimerase derived from Flavonifractor plautii
- tryptophan (Trp) at position 29 is substituted with lysine (Lys)
- glycine (Gly) at position 216 is substituted with serine (Ser)
- methionine present at position 234 (Met) previously applied for a patent for a novel D-allulose epimerase variant W29K/G216S/M234I substituted with isoleucine (Ile) [Korean Patent Publication No.
- the wild-type D-allulose 3-epimerase derived from Flavonifractor plautii consists of the amino acid sequence of SEQ ID NO: 1, and a polynucleotide encoding the wild-type D-allulose 3-epimerase.
- the fragment consists of the nucleotide sequence of SEQ ID NO: 2.
- the D-allulose epimerase variant W29K / G216S / M234I consists of the amino acid sequence of SEQ ID NO: 3, and the polynucleotide fragment encoding the amino acid sequence of the D-allulose epimerase variant W29K / G216S / M234I It consists of the nucleotide sequence of SEQ ID NO: 4.
- the inventors of the present invention modified the amino acid sequence of D-allulose epimerase variant W29K/G216S/M234I to improve the conversion rate of fructose to allulose and thermal stability. Based on this, the protein structure was predicted using a homology modeling technique, and amino acid substitution sites were searched. The homology modeling was performed using the Robetta server, and protein structure prediction and analysis were performed using software programs such as Coot, PyMol, and UCSF Chimera. A total of four amino acid residue positions expected to be related to conversion and thermal stability improvement when chemical bonds are changed through three-dimensional structural model analysis of D-allulose epimerase variants W29K/G216S/M234I and amino acids to be substituted at these positions Residues were selected.
- Figure 1 shows a total of four amino acid residue positions selected as substitution candidates to improve the conversion rate of fructose to allulose and thermal stability of the D-allulose epimerase variant W29K/G216S/M234I by the inventors of the present invention.
- A77 represents alanine (Als) present at position 77 of the amino acid sequence of SEQ ID NO: 3
- E173 represents glutamic acid (Glu) present at position 173 of the amino acid sequence of SEQ ID NO: 3.
- W209 represents tryptophan (Trp) present at position 209 of the amino acid sequence of SEQ ID NO: 3
- Q240 represents glutamine (Gln) present at position 240 of the amino acid sequence of SEQ ID NO: 3.
- an enzyme variant W29K/A77S/G216S/M234I composed of the amino acid sequence of SEQ ID NO: 5 was prepared by replacing alanine (Als) at position 77 of the amino acid sequence of SEQ ID NO: 3 with serine (Ser).
- glutamic acid (Glu) present at position 173 of the amino acid sequence of SEQ ID NO: 3 was substituted with alanine (Ala) to prepare an enzyme variant W29K / E173A / G216S / M234I consisting of the amino acid sequence of SEQ ID NO: 6, SEQ ID NO:
- the enzyme variant W29K / W209L / G216S / M234I consisting of the amino acid sequence of SEQ ID NO: 7 was prepared by replacing tryptophan (Trp) at position 209 of the amino acid sequence of SEQ ID NO: 3 with leucine (Leu), and the amino acid sequence of SEQ ID NO: 3
- the enzyme variant W29K/G216S/M234I/Q240D consisting of the amino acid sequence of SEQ ID NO: 8 was prepared by replacing glutamine (Gln) at position 240 with aspartic acid (Asp).
- Example 2 Flavonifractor Flourti ( Flavonifractor plautii ) Production of recombinant vectors and recombinant strains for overexpression of D-allulose 3-epimerase variants
- a PCR reaction was performed using the primers shown in Table 1 to prepare a gene encoding an allulose epimerase variant derived from Flavonifractor plautii .
- 1 pM of the oligonucleotide which is the primer of Table 1
- a reaction solution to which 100 ⁇ M of deoxynucleotide triphosphate (dATP, dCTP, dGTP, dTTP) was added
- D-allulose epimerase variant W29K used as a template (template) /G216S/M234I polynucleotide (SEQ ID NO: 4) 100 ng was mixed and PCR was performed at 25 to 30 cycles in the presence of 1 unit of pfu-X DNA polymerase mixture (Bioneer) using a thermocycler (TP600, TAKARA BIO Inc., JAPAN) reaction was carried out.
- the base sequence of SEQ ID NO: 9 represents a polynucleotide fragment encoding the amino acid sequence of enzyme variant W29K/A77S/G216S/M234I
- the base sequence of SEQ ID NO: 10 represents the amino acid sequence of enzyme variant W29K/E173A/G216S/M234I.
- the base sequence of SEQ ID NO: 11 represents a polynucleotide fragment encoding the amino acid sequence of enzyme variant W29K/W209L/G216S/M234I
- the base sequence of SEQ ID NO: 12 represents enzyme variant W29K/G216S/M234I/Q240D It represents a polynucleotide fragment encoding the amino acid sequence of.
- the nucleotide sequences of SEQ ID NOs: 9 to 12 are composed of nucleotide sequences directly corresponding to the amino acid sequences of the enzyme variants, and the sequence of the restriction enzyme recognition site is omitted for convenience.
- the prepared polynucleotide fragment was inserted into the same restriction enzyme site of pET28a (Novagen), an expression vector, using restriction enzymes NdeI and XhoI to construct four recombinant expression vectors.
- the recombinant expression vector was introduced into and transformed into E. coli BL21(DE3) (invitrogen) using the heat shock method (see Sambrook and Russell: Molecular Cloning.), and four recombinant E. coli strains were prepared. A 60% glycerin solution was added to the prepared recombinant E. coli, and stored frozen at -70°C before culturing for enzyme expression.
- Example 3 Flavonifractor Flourti ( Flavonifractor plautii ) Expression and purification of D-allulose 3-epimerase variants derived from
- the overexpressed allulose epimerase mutant was isolated in the following manner. First, the culture medium of recombinant E. coli was centrifuged for about 15 minutes at 4100 ⁇ g and 4° C. to remove the supernatant, and the cells of recombinant E. coli were recovered. Thereafter, the recovered recombinant E. coli cells were suspended in lysis buffer (containing 50 mM potassium monophosphate, 300 mM potassium chloride, and 5 mM imidazole), and then treated with a sonicator to disrupt the cells. Thereafter, the cell lysate was centrifuged at 15,814 ⁇ g and 4° C. for about 10 minutes to remove the cell pellet, and only the supernatant was recovered. Thereafter, a purified enzyme solution containing an allulose epimerase variant was separated from the recovered supernatant using a His-tag affinity chromatography column and a desalting column.
- lysis buffer containing 50 mM potassium monophosphate, 300 mM potassium
- D-allulose epimerase variant W29K/G216S/M234I [Korean Patent Publication No. 10-2021-0132405 (2021.11.04)] previously filed by the applicant of the present invention and D- Conversion rate of fructose to allulose of four allulose epimerase variants (W29K/A77S/G216S/M234I, W29K/E173A/G216S/M234I, W29K/W209L/G216S/M234I, W29K/G216S/M234I/Q240D) and In order to confirm thermal stability, the enzyme was exposed to a high temperature for a certain period of time, and then the degree of reduction in the conversion activity of fructose to allulose was analyzed.
- the W29K/G216S/M234I purified enzyme solution obtained in Example 3 of Korean Patent Publication No. 10-2021-0132405 (2021.11.04) (enzyme concentration 0.3 mg/ml) and the obtained in Example 3 of the present invention
- the purified enzyme solution (enzyme concentration: 0.3 mg/ml) was stored in a constant temperature water bath at 62° C. for 0 hr, 0.5 hr, 1 hr, 1.5 hr, and 2 hr, followed by heat treatment.
- the heat-treated purified enzyme solution was added to 50 mM PIPES buffer (pH 7.0) containing 10% (w/w) fructose and 1 mM manganese sulfate (MnSO 4 ) metal ions so that the enzyme concentration was 75 ⁇ g/ml. It was reacted for 10 minutes under a temperature condition of 62 ° C. and a shaking condition of 120 rpm using a shaking constant temperature water bath (VS-1205SW1, vision science). Thereafter, the temperature of the reaction product was lowered to 4° C. to stop the reaction, and the supernatant was recovered by centrifugation at 16,600 ⁇ g and 4° C.
- PIPES buffer pH 7.0
- MnSO 4 manganese sulfate
- HPLC high-performance liquid chromatography
- Table 4 shows the conversion rate of fructose to allulose for each heat treatment condition when the D-allulose 3-epimerase variant derived from Flavonifractor plautii was heat-treated.
- the D-allulose 3-epimerase variant W29K / A77S / G216S / M234I is an allulose of similar or higher fructose than the D-allulose 3-epimerase variant W29K / G216S / M234I regardless of the heat treatment time. showed conversion activity, and especially showed remarkably improved thermal stability.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
프라이머 설명 | 프라이머 염기 서열(5'→3') |
A77S 순방향 프라이머 | AATACGACCTGAGCAGCGACGATCCGGCGGTG |
A77S 역방향 프라이머 | GATCGTCGCTGCTCAGGTCGTATTTGGCCTCCA |
E173A 순방향 프라이머 | AAGAGGGCGTGGCGTTTGTCAAGCGCCTGGGC |
E173A 역방향 프라이머 | CGCTTGACAAACGCCACGCCCTCTTTGGCGGT |
W209L 순방향 프라이머 | AGGCGGGCCCCCTGCTGGGGCATTTCCACGTG |
W209L 역방향 프라이머 | AATGCCCCAGCAGGGGGCCCGCCTCCAGAATG |
Q240D 순방향 프라이머 | GCCGCCCTCAAGGATGTGAACTACCAGGGGGCC |
Q240D 역방향 프라이머 | CTGGTAGTTCACATCCTTGAGGGCGGCGGCAAT |
프라이머 설명 | 프라이머 염기 서열(5'→3') |
NdeI 순방향 프라이머 | GCATGCCATATGAACCCGATTGGAATGCA |
XhoI 역방향 프라이머 | GCATGCCTCGAGCGCGGTCAGCTCCTTGAGGA |
배지 성분 | 함량 | 배지 성분 | 함량 |
글리세롤(Glycerol) | 9.0 중량% | MgSO4 | 0.1 중량% |
락토스(Lactose) | 1.0 중량% | FeSO4 | 10.0 ppm |
(NH4)2SO4 | 0.6 중량% | MnSO4 | 10.0 ppm |
KH2PO4 | 0.5 중량% | ZnSO4 | 10.0 ppm |
YPA | 1.5 중량% | 소포제(네오린) | 1.0 drop |
62℃에서의 열처리 시간 | 알룰로스 에피머화 효소변이체의 열처리 시간별 과당의 알룰로스로의 전환율(%) | ||||
W29K/G216G/M234I | W29K/A77S/G216S/M234I | W29K/E173A/G216S/M234I | W29K/W209L/G216S/M234I | W29K/G216S/M234I/Q240D | |
0 hr | 9.88 | 9.86 | 9.08 | 9.47 | 8.78 |
0.5 hr | 6.59 | 7.31 | 5.73 | 6.29 | 6.01 |
1 hr | 5.69 | 6.09 | 4.55 | 5.44 | 5.01 |
1.5 hr | 4.50 | 4.88 | 3.66 | 4.38 | 4.15 |
2 hr | 4.06 | 4.33 | 3.32 | 3.92 | 3.70 |
Claims (10)
- 서열번호 5의 아미노산 서열로 이루어진 알룰로스 에피머화 효소 변이체.
- 제1항의 알룰로스 에피머화 효소 변이체를 코딩하는 폴리뉴클레오티드.
- 제2항에 있어서, 상기 폴리뉴클레오티드는 서열번호 9의 염기 서열로 이루어진 것을 특징으로 하는 폴리뉴클레오티드.
- 제2항의 폴리뉴클레오티드를 포함하는 재조합 벡터.
- 제2항의 폴리뉴클레오티드, 제3항의 폴리뉴클레오티드 또는 제4항의 재조합 벡터 중 어느 하나에 의해 형질전환된 재조합 균주.
- 제5항의 재조합 균주를 배양하여 알룰로스 에피머화 효소 변이체를 발현시키는 단계; 및상기 알룰로스 에피머화 효소 변이체가 발현된 재조합 균주의 파쇄물로부터 알룰로스 에피머화 효소 변이체를 분리하는 단계를 포함하는 알룰로스 에피머화 효소 변이체의 제조방법.
- 제1항의 알룰로스 에피머화 효소 변이체를 포함하는 알룰로스 생산용 조성물.
- 제5항의 재조합 균주, 상기 재조합 균주의 배양물 또는 상기 재조합 균주의 파쇄물을 포함하는 알룰로스 생산용 조성물.
- 과당을 제1항의 알룰로스 에피머화 효소 변이체 또는 상기 알룰로스 에피머화 효소 변이체를 포함하는 조성물과 반응시키는 단계를 포함하는 알룰로스의 제조방법.
- 과당을 제5항의 재조합 균주, 상기 재조합 균주의 배양물, 상기 재조합 균주의 파쇄물 또는 이들 중 어느 하나 이상을 포함하는 조성물과 반응시키는 단계를 포함하는 알룰로스의 제조방법.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180084320.8A CN116917481A (zh) | 2021-11-19 | 2021-11-22 | 热稳定性优秀的阿洛酮糖差向异构酶变异体、其制备方法及利用其的阿洛酮糖的制备方法 |
EP21964881.3A EP4249595A1 (en) | 2021-11-19 | 2021-11-22 | Allulose epimerase variant with excellent thermal stability, preparation method therefor, and preparation method for allulose using same |
US18/267,874 US20240052389A1 (en) | 2021-11-19 | 2021-11-22 | Allulose epimerase variant with excellent thermal stability, preparation method therefor, and preparation method for allulose using same |
JP2023537243A JP2023554112A (ja) | 2021-11-19 | 2021-11-22 | 熱安定性に優れたアルロースエピマー化酵素変異体、その製造方法およびこれを用いたアルロースの製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210160438A KR20230073739A (ko) | 2021-11-19 | 2021-11-19 | 열 안정성이 우수한 알룰로스 에피머화 효소 변이체, 이의 제조방법 및 이를 이용한 알룰로스의 제조방법 |
KR10-2021-0160438 | 2021-11-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023090495A1 true WO2023090495A1 (ko) | 2023-05-25 |
Family
ID=86397130
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/017155 WO2023090495A1 (ko) | 2021-11-19 | 2021-11-22 | 열 안정성이 우수한 알룰로스 에피머화 효소 변이체, 이의 제조방법 및 이를 이용한 알룰로스의 제조방법 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20240052389A1 (ko) |
EP (1) | EP4249595A1 (ko) |
JP (1) | JP2023554112A (ko) |
KR (1) | KR20230073739A (ko) |
CN (1) | CN116917481A (ko) |
WO (1) | WO2023090495A1 (ko) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100744479B1 (ko) | 2005-06-01 | 2007-08-01 | 씨제이 주식회사 | 사이코스 에피머화 효소에 의한 사이코스의 생산 방법 |
KR100832339B1 (ko) | 2006-12-11 | 2008-05-26 | 솔젠트 (주) | 과당을 사이코스로 전환하는 신규한 시노리조비움 속균주와 이를 이용한 사이코스 생산법 |
KR101106253B1 (ko) | 2009-10-16 | 2012-01-18 | 경상대학교산학협력단 | 사이코스 3-에피머라제 효소를 코딩하는 폴리뉴클레오티드를 포함하는 대장균 및 그를 이용하여 사이코스를 생산하는 방법 |
KR101203856B1 (ko) | 2011-08-24 | 2012-11-21 | 씨제이제일제당 (주) | 열 안정성이 향상된 사이코스 에피머화 효소 변이체 및 이를 이용한 사이코스의 연속적 생산 |
KR101318422B1 (ko) | 2013-04-09 | 2013-10-15 | 주식회사 삼양제넥스 | D-사이코스 에피머화 효소, 및 이를 이용하는 사이코스 생산방법 |
KR101339443B1 (ko) | 2005-11-15 | 2013-12-06 | 가부시기가이샤하야시바라 | 케토오스 3-에피머라아제와 그 제조 방법 및 용도 |
KR20140021974A (ko) | 2012-08-10 | 2014-02-21 | 주식회사 삼양제넥스 | 사이코스 에피머화 효소 및 이를 이용한 사이코스로 전환용 조성물 |
KR101473918B1 (ko) | 2014-05-28 | 2014-12-17 | 대상 주식회사 | 사이코스 에피머화 효소, 이의 제조방법 및 이를 이용한 사이코스의 제조방법 |
KR102254411B1 (ko) | 2019-12-19 | 2021-05-24 | 대상 주식회사 | 알룰로스 에피머화 효소 변이체, 이의 제조방법 및 이를 이용한 알룰로스의 제조방법 |
KR20210132405A (ko) | 2020-04-27 | 2021-11-04 | 대상 주식회사 | 알룰로스 에피머화 효소 변이체, 이의 제조방법 및 이를 이용한 알룰로스의 제조방법 |
-
2021
- 2021-11-19 KR KR1020210160438A patent/KR20230073739A/ko unknown
- 2021-11-22 WO PCT/KR2021/017155 patent/WO2023090495A1/ko active Application Filing
- 2021-11-22 JP JP2023537243A patent/JP2023554112A/ja active Pending
- 2021-11-22 CN CN202180084320.8A patent/CN116917481A/zh active Pending
- 2021-11-22 EP EP21964881.3A patent/EP4249595A1/en active Pending
- 2021-11-22 US US18/267,874 patent/US20240052389A1/en active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100744479B1 (ko) | 2005-06-01 | 2007-08-01 | 씨제이 주식회사 | 사이코스 에피머화 효소에 의한 사이코스의 생산 방법 |
KR101339443B1 (ko) | 2005-11-15 | 2013-12-06 | 가부시기가이샤하야시바라 | 케토오스 3-에피머라아제와 그 제조 방법 및 용도 |
KR100832339B1 (ko) | 2006-12-11 | 2008-05-26 | 솔젠트 (주) | 과당을 사이코스로 전환하는 신규한 시노리조비움 속균주와 이를 이용한 사이코스 생산법 |
KR101106253B1 (ko) | 2009-10-16 | 2012-01-18 | 경상대학교산학협력단 | 사이코스 3-에피머라제 효소를 코딩하는 폴리뉴클레오티드를 포함하는 대장균 및 그를 이용하여 사이코스를 생산하는 방법 |
KR101203856B1 (ko) | 2011-08-24 | 2012-11-21 | 씨제이제일제당 (주) | 열 안정성이 향상된 사이코스 에피머화 효소 변이체 및 이를 이용한 사이코스의 연속적 생산 |
KR20140021974A (ko) | 2012-08-10 | 2014-02-21 | 주식회사 삼양제넥스 | 사이코스 에피머화 효소 및 이를 이용한 사이코스로 전환용 조성물 |
KR101318422B1 (ko) | 2013-04-09 | 2013-10-15 | 주식회사 삼양제넥스 | D-사이코스 에피머화 효소, 및 이를 이용하는 사이코스 생산방법 |
KR101473918B1 (ko) | 2014-05-28 | 2014-12-17 | 대상 주식회사 | 사이코스 에피머화 효소, 이의 제조방법 및 이를 이용한 사이코스의 제조방법 |
KR102254411B1 (ko) | 2019-12-19 | 2021-05-24 | 대상 주식회사 | 알룰로스 에피머화 효소 변이체, 이의 제조방법 및 이를 이용한 알룰로스의 제조방법 |
KR20210132405A (ko) | 2020-04-27 | 2021-11-04 | 대상 주식회사 | 알룰로스 에피머화 효소 변이체, 이의 제조방법 및 이를 이용한 알룰로스의 제조방법 |
Non-Patent Citations (4)
Title |
---|
CHUL-SOON PARK, KIM TAEYONG, HONG SEUNG-HYE, SHIN KYUNG-CHUL, KIM KYOUNG-ROK, OH DEOK-KUN: "D-Allulose Production from D-Fructose by Permeabilized Recombinant Cells of Corynebacterium glutamicum Cells Expressing D-Allulose 3-Epimerase Flavonifractor plautii", PLOS ONE, vol. 11, no. 7, 28 July 2016 (2016-07-28), pages e0160044, XP055703039, DOI: 10.1371/journal.pone.0160044 * |
DEUSCHER, M.: "Guide to Protein Purification Methods Enzymology", vol. 182, 1990, ACADEMIC PRESS. INC. |
PATEL SATYA NARAYAN, GIRIJA KAUSHAL, SUDHIR P. SINGH: "A novel D-allulose 3-epimerase gene from the metagenome of a thermal aquatic habitat and D-allulose production by Bacillus subtilis whole-cell catalysis", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 86, no. 5, 1 March 2020 (2020-03-01), XP093068850 * |
SAMBROOK ET AL.: "Molecular Cloning: A laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS |
Also Published As
Publication number | Publication date |
---|---|
KR20230073739A (ko) | 2023-05-26 |
EP4249595A1 (en) | 2023-09-27 |
JP2023554112A (ja) | 2023-12-26 |
US20240052389A1 (en) | 2024-02-15 |
CN116917481A (zh) | 2023-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015182937A1 (ko) | 사이코스 에피머화 효소 및 이를 이용한 사이코스의 제조방법 | |
KR100872694B1 (ko) | 코리네박테리움 속 균주로부터 발현된 아라비노스이성화효소 및 그를 이용한 타가토스의 제조방법 | |
KR102132381B1 (ko) | 아스로박터 글로비포미스에 의해 생산되는 케토오스 3-에피머라제 | |
CN110462036B (zh) | 一种新型d-阿洛酮糖3-差向异构酶以及使用该酶制备d-阿洛酮糖的方法 | |
WO2021221418A1 (ko) | 알룰로스 에피머화 효소 변이체, 이의 제조방법 및 이를 이용한 알룰로스의 제조방법 | |
EP3865574B1 (en) | Allulose epimerase variant, method for producing same, and method for producing allulose using same | |
WO2021125514A1 (ko) | 알룰로스 에피머화 효소 변이체, 이의 제조방법 및 이를 이용한 알룰로스의 제조방법 | |
RU2730602C2 (ru) | Новая полифосфат-зависимая глюкокиназа и способ получения глюкозо-6-фосфата с ее использованием | |
KR102114865B1 (ko) | 신규한 사이코스-6-인산 탈인산효소, 상기 효소를 포함하는 사이코스 생산용 조성물, 상기 효소를 이용하여 사이코스를 제조하는 방법 | |
WO2023090495A1 (ko) | 열 안정성이 우수한 알룰로스 에피머화 효소 변이체, 이의 제조방법 및 이를 이용한 알룰로스의 제조방법 | |
CN114196696A (zh) | 一种与特定短肽标签融合能高效催化Reb M生成的重组酶 | |
KR102232837B1 (ko) | 글루코실글리세롤 생산 활성을 가지는 신규한 폴리펩티드 및 이를 이용한 글루코실글리세롤 제조방법 | |
EP4257689A1 (en) | Novel promoter variant for constitutive expression and use thereof | |
KR102232839B1 (ko) | 투라노스 생산 활성을 가지는 신규한 폴리펩티드 및 이를 이용한 투라노스 제조방법 | |
CN112867793B (zh) | 新型果糖-c4-差向异构酶及使用其制备塔格糖的方法 | |
KR101841267B1 (ko) | 라이보스-5-인산 이성화효소, 이의 제조방법 및 이를 이용한 알로스의 제조방법 | |
KR100702254B1 (ko) | 호열성 및 호염기성 l-아라비노스 이성화효소 | |
CN111212907A (zh) | 一种果糖-4-差向异构酶以及使用其制备塔格糖的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 202180084320.8 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18267874 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023537243 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2021964881 Country of ref document: EP Effective date: 20230619 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21964881 Country of ref document: EP Kind code of ref document: A1 |